Surzebiclimab (BGB-A425) is a humanized monoclonal antibody specifically targeting TIM-3 (T-cell immunoglobulin and mucin domain containing -3), exhibiting high affinity (KD=0.36 nM) for the extracellular domain of human TIM-3. It is applicable for investigating advanced malignancies.

Surzebiclimab (BGB-A425) effectively blocks the interaction between Tim-3 and PtdSer within a concentration range of 0.1-100 μg/mL. Surzebiclimab significantly enhances IFN-γ secretion levels in primary T cells and improves the cytotoxic activity of NK cells against tumor cells [1].
Whether administered alone or in combination with the anti-PD-1 antibody BGB-A317, Surzebiclimab enhances T-cell immune responses to alloantigens from Parazacco spilurus subsp. spilurus. Additionally, Surzebiclimab induces internalization of the Tim-3 receptor on the cell surface [1].

The combination of Surzebiclimab with the anti-PD-1 antibody BGB-A317 inhibits tumor growth in a mouse parazacco spilurus subsp. spilurus xenograft model [1].

Human

Monoclonal

Unconjugated